ConductScience.org, home

Paper40762016

Neoadjuvant immunotherapy for resectable primary liver cancer (Review).

Deng Q and 3 others. Oncol Lett, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Neoadjuvant immunotherapy for resectable primary liver cancer (Review). Papers, record 40762016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40762016

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoadjuvant immunotherapy for resectable primary liver cancer (Review).
PubMed
Journal
Oncol Lett
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-08-07
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Deng QQingsong
2He MMinglian
3Zhang LLeida
4Wu YYuzhang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References143

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115221919Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.J Surg Oncol2004https://conductscience.org/library/papers/15221919PubMed
231358424Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy.Semin Diagn Pathol2019https://conductscience.org/library/papers/31358424PubMed
338954360Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics.Hepatol Int2024https://conductscience.org/library/papers/38954360PubMed
431781831Immune capacity determines outcome following surgery or trauma: a systematic review and meta-analysis.Eur J Trauma Emerg Surg2020https://conductscience.org/library/papers/31781831PubMed
518566595How regulatory T cells work.Nat Rev Immunol2008https://conductscience.org/library/papers/18566595PubMed
639255928Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.J Hepatol2025https://conductscience.org/library/papers/39255928PubMed
727663893Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.Cancer Discov2016https://conductscience.org/library/papers/27663893PubMed
831065295Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.Ther Adv Med Oncol2019https://conductscience.org/library/papers/31065295PubMed
931686845Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report.Onco Targets Ther2019https://conductscience.org/library/papers/31686845PubMed
1032359091Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.Int J Cancer2020https://conductscience.org/library/papers/32359091PubMed
1135004667Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.Front Cell Dev Biol2021https://conductscience.org/library/papers/35004667PubMed
1232951909Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?J Hepatol2020https://conductscience.org/library/papers/32951909PubMed
137672764Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem.Hepatogastroenterology1995https://conductscience.org/library/papers/7672764PubMed
1425010665Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.Ann Surg2015https://conductscience.org/library/papers/25010665PubMed
1539527136Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.Cancer Immunol Immunother2024https://conductscience.org/library/papers/39527136PubMed
1634575463Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.Pharmaceutics2021https://conductscience.org/library/papers/34575463PubMed
1731262965Electroporation.Cold Spring Harb Protoc2019https://conductscience.org/library/papers/31262965PubMed
1836727075Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.Front Oncol2022https://conductscience.org/library/papers/36727075PubMed
1926826241Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1.J Immunol2016https://conductscience.org/library/papers/26826241PubMed
2028425018Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.Curr Treat Options Gastroenterol2017https://conductscience.org/library/papers/28425018PubMed

See all 143 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42645397The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma.Curr Oncol2026https://conductscience.org/library/papers/42645397

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40762016

GET https://conductscience.org/api/papers/v1/40762016/references?page=2